Company: ZLAB
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001628280-25-023411
Chunk: 74

Company: Zai Lab Ltd
Filing Date: 2025-05-08
Form: 10-Q
Item: Part I, Item 8
Chunk 74
---
:Three Months Ended March 31,20252024Personnel compensation and related costs24,079 28,008 Licensing fees19,997 — CROs/CMOs/Investigators expenses9,830 19,904 Other costs6,823 6,733 Total research and development expenses60,729 54,645 

15

Zai Lab Limited Notes to the unaudited condensed consolidated financial statements 

Three Months Ended March 31,20252024Clinical programs28,092 18,788 Pre-Clinical programs3,314 2,049 Unallocated research and development expenses29,323 33,808 Total research and development expenses60,729 54,645 Three Months Ended March 31,20252024Personnel compensation and related costs40,643 45,894 Other costs22,779 23,300 Total selling, general, and administrative expenses63,422 69,194 Three Months Ended March 31,20252024Selling and marketing expenses41,939 43,594 General and administrative expenses21,483 25,600 Total selling, general, and administrative expenses63,422 69,194 

16

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis of our financial condition and results of operations together with our 2024 Annual Report and our unaudited condensed consolidated financial statements and the accompanying notes for the first quarter of 2025 included in Item 1. Financial Statements. 

Overview 

We are a patient-focused, innovative, commercial-stage, global biopharmaceutical company with a substantial presence in both Greater China and the United States. We are focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. We intend to leverage our competencies and resources to positively impact human health in Greater China and worldwide. We currently have seven commercial programs – ZEJULA,VYVGART / VYVGART Hytrulo, NUZYRA, OPTUNE, QINLOCK, XACDURO, and AUGTYRO – with products that have received marketing approval and that we have commercially launched in one or more territories in Greater China. We also have multiple programs in late-stage product development and a number of ongoing pivotal trials across our portfolio.

Since our inception, we have incurred